|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.50 GBX | -4.93% |
|
0.00% | +16.38% |
| 24/02 | Avacta hails new data supporting proprietary preCision platform | AN |
| 24/02 | Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 36.36L | 29.41L | 96.53L | 2.32Cr | 1L | |||||
Total Revenues | 36.36L | 29.41L | 96.53L | 2.32Cr | 1L | |||||
Cost of Goods Sold, Total | 24.62L | 38.88L | 34.6L | 1.2Cr | - | |||||
Gross Profit | 11.74L | -9L | 61.93L | 1.12Cr | 1L | |||||
Selling General & Admin Expenses, Total | 73.15L | 81.36L | 1.12Cr | 1.69Cr | 1.2Cr | |||||
Stock-Based Compensation (IS) | 31.08L | 50.58L | 74.9L | 29.06L | 41.07L | |||||
R&D Expenses | 89.61L | 1.35Cr | 1.11Cr | 1.45Cr | 1.43Cr | |||||
Depreciation & Amortization - (IS) | 11.25L | 14.62L | 19.04L | 26.38L | 14.89L | |||||
Amortization of Goodwill and Intangible Assets - (IS) | - | - | - | 10.33L | 16T | |||||
Other Operating Expenses, Total | 2.05Cr | 2.81Cr | 3.17Cr | 3.8Cr | 3.19Cr | |||||
Operating Income | -1.93Cr | -2.91Cr | -2.55Cr | -2.67Cr | -3.18Cr | |||||
Interest Expense, Total | -93T | -1L | -27.01L | -1.53Cr | -98.54L | |||||
Interest And Investment Income | 43T | 17T | 91T | 7L | 7L | |||||
Net Interest Expenses | -50T | -1L | -26.1L | -1.46Cr | -91.91L | |||||
Income (Loss) On Equity Invest. | -2L | - | -11.52L | -8L | -7L | |||||
Other Non Operating Income (Expenses) | - | - | -41L | 1.57Cr | 1.28Cr | |||||
EBT, Excl. Unusual Items | -1.96Cr | -2.92Cr | -3.34Cr | -2.65Cr | -2.9Cr | |||||
Merger & Related Restructuring Charges | - | - | -30.22L | -3L | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Asset Writedown | -17.41L | - | -52.25L | -5L | - | |||||
EBT, Incl. Unusual Items | -2.13Cr | -2.92Cr | -4.16Cr | -2.73Cr | -2.9Cr | |||||
Income Tax Expense | -24.52L | -28.2L | -21.02L | -23.7L | 4L | |||||
Earnings From Continuing Operations | -1.89Cr | -2.64Cr | -3.95Cr | -2.49Cr | -2.94Cr | |||||
Earnings Of Discontinued Operations | - | 58T | 4L | - | -2.34Cr | |||||
Net Income to Company | -1.89Cr | -2.63Cr | -3.92Cr | -2.49Cr | -5.28Cr | |||||
Net Income - (IS) | -1.89Cr | -2.63Cr | -3.92Cr | -2.49Cr | -5.28Cr | |||||
Net Income to Common Incl Extra Items | -1.89Cr | -2.63Cr | -3.92Cr | -2.49Cr | -5.28Cr | |||||
Net Income to Common Excl. Extra Items | -1.89Cr | -2.64Cr | -3.95Cr | -2.49Cr | -2.94Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.08 | -0.11 | -0.15 | -0.09 | -0.15 | |||||
Basic EPS - Continuing Operations | -0.08 | -0.11 | -0.15 | -0.09 | -0.09 | |||||
Basic Weighted Average Shares Outstanding | 23Cr | 25Cr | 26Cr | 27Cr | 34Cr | |||||
Net EPS - Diluted | -0.08 | -0.11 | -0.15 | -0.09 | -0.15 | |||||
Diluted EPS - Continuing Operations | -0.08 | -0.11 | -0.15 | -0.09 | -0.09 | |||||
Diluted Weighted Average Shares Outstanding | 23Cr | 25Cr | 26Cr | 27Cr | 34Cr | |||||
Normalized Basic EPS | -0.05 | -0.07 | -0.08 | -0.06 | -0.05 | |||||
Normalized Diluted EPS | -0.05 | -0.07 | -0.08 | -0.06 | -0.05 | |||||
Supplemental Items | ||||||||||
EBITDA | -1.84Cr | -2.76Cr | -2.43Cr | -2.46Cr | -3.04Cr | |||||
EBITA | -1.93Cr | -2.91Cr | -2.54Cr | -2.57Cr | -3.18Cr | |||||
EBIT | -1.93Cr | -2.91Cr | -2.55Cr | -2.67Cr | -3.18Cr | |||||
EBITDAR | -1.84Cr | -2.76Cr | -2.43Cr | -2.44Cr | -3.02Cr | |||||
Effective Tax Rate - (Ratio) | 11.49 | 9.66 | 5.05 | 8.68 | -1.53 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Total Current Taxes | -24.52L | -28.2L | -20.39L | -20.91L | -18.23L | |||||
Total Deferred Taxes | - | - | -63T | -3L | 22.67L | |||||
Normalized Net Income | -1.23Cr | -1.82Cr | -2.09Cr | -1.66Cr | -1.81Cr | |||||
Interest on Long-Term Debt | 93T | 1L | 28.34L | 1.53Cr | 1.02Cr | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 99.68L | 1.43Cr | 1.71Cr | 1.46Cr | 1.43Cr | |||||
Net Rental Expense, Total | 2T | 29T | 42T | 2L | 2L | |||||
Imputed Operating Lease Interest Expense | 1.04T | 15.86T | 28.08T | 5L | 3L | |||||
Imputed Operating Lease Depreciation | 961 | 13.14T | 13.92T | -3L | -2L | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 31.08L | 50.58L | 74.9L | 29.06L | 41.07L | |||||
Total Stock-Based Compensation | 31.08L | 50.58L | 74.9L | 29.06L | 41.07L |
- Stock Market
- Equities
- AVCT Stock
- Financials Avacta Group Plc
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















